---
title: "EDIT.US (EDIT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EDIT.US/news.md"
symbol: "EDIT.US"
name: "EDIT.US"
parent: "https://longbridge.com/en/quote/EDIT.US.md"
datetime: "2026-06-14T03:31:39.789Z"
locales:
  - [en](https://longbridge.com/en/quote/EDIT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EDIT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EDIT.US/news.md)
---

# EDIT.US (EDIT.US) — Related News

### [CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?](https://longbridge.com/en/news/288179361.md)
*2026-05-31T17:10:31.000Z*
> This article compares CRISPR Therapeutics and Editas Medicine as investment options for 2026. CRISPR holds a first-mover

### [Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX](https://longbridge.com/en/news/287880941.md)
*2026-05-28T08:13:51.000Z*
> Today's Top Gainers list highlights Q32 Bio, which surged over 85% after announcing a $55 million private placement fina

### [Editas Medicine Announces Proposed Public Offering | EDIT Stock News](https://longbridge.com/en/news/287617765.md)
*2026-05-26T02:15:27.000Z*
> Editas Medicine Announces Proposed Public Offering | EDIT Stock News

### [Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | EDIT Stock News](https://longbridge.com/en/news/287640208.md)
*2026-05-26T05:05:45.000Z*
> Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | EDIT Stock News